Phase II study of docetaxel/cisplatin/5-fluorouracil combination chemotherapy for advanced esophageal cancer
Phase 2
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000008400
- Lead Sponsor
- Jikei university school of medicine, department of oncology and hematology, department of gastroenterological surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Known hypersensitivity to taxanes, platinum, fluoropyrimidines. Known dihydropyrimidine-dehydrogenase (DPD) deficit. (2) Pre-existing motor or sensory neurotoxicity of a severity => Grade2 (3) Active infectious diseases. (4) Symptomatic bleeding tendency, coagulation disorder, or coagulation factor deficiency. (5) Uncontrollable hypertension, uncontrollable diabetes, unstable angina, or heart failure. (6) Pre-existing renal insufficiency or proteinuria => 2+. (7) Clinical or radiographic signs of interstitial pneumonia or pulmonary fibrosis. (8) Active gastrointestinal bleeding, bowel obstruction. (9) Patients who are judged inappropriate for the entry into this study by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method